PL3515489T3 - Kompozycje białek wiążących cd80 i cd86 oraz ich zastosowania - Google Patents

Kompozycje białek wiążących cd80 i cd86 oraz ich zastosowania

Info

Publication number
PL3515489T3
PL3515489T3 PL17851784.3T PL17851784T PL3515489T3 PL 3515489 T3 PL3515489 T3 PL 3515489T3 PL 17851784 T PL17851784 T PL 17851784T PL 3515489 T3 PL3515489 T3 PL 3515489T3
Authority
PL
Poland
Prior art keywords
binding protein
protein compositions
compositions
binding
protein
Prior art date
Application number
PL17851784.3T
Other languages
English (en)
Inventor
Yang Liu
Martin DEVENPORT
Pan Zheng
Wei Wu
Xuexiang DU
Mingyue LIU
Fei Tang
Original Assignee
OncoC4, Inc.
Children's Research Institute, Children's National Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OncoC4, Inc., Children's Research Institute, Children's National Medical Center filed Critical OncoC4, Inc.
Publication of PL3515489T3 publication Critical patent/PL3515489T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17851784.3T 2016-09-19 2017-09-19 Kompozycje białek wiążących cd80 i cd86 oraz ich zastosowania PL3515489T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662396667P 2016-09-19 2016-09-19
PCT/US2017/052264 WO2018053506A1 (en) 2016-09-19 2017-09-19 Cd80 and cd86 binding protein compositions and uses thereof

Publications (1)

Publication Number Publication Date
PL3515489T3 true PL3515489T3 (pl) 2026-03-16

Family

ID=61618947

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17851784.3T PL3515489T3 (pl) 2016-09-19 2017-09-19 Kompozycje białek wiążących cd80 i cd86 oraz ich zastosowania

Country Status (7)

Country Link
US (3) US11261233B2 (pl)
EP (2) EP3515489B1 (pl)
CN (2) CN109715210B (pl)
DK (1) DK3515489T3 (pl)
ES (1) ES3059995T3 (pl)
PL (1) PL3515489T3 (pl)
WO (1) WO2018053506A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3389699T1 (sl) 2015-12-15 2024-07-31 OncoC4, Inc. Himerna in humanizirana monoklonska protitelesa proti humanemu ctla4 in uporabe le - teh
EP3515489B1 (en) * 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
WO2020161045A1 (en) 2019-02-04 2020-08-13 Assistance Publique - Hôpitaux De Paris Method for treating checkpoint inhibitors induced adverse events
CN110063970B (zh) * 2019-04-30 2024-09-03 上海心脉途医疗科技有限公司 与irAE相关的肠道菌群及irAE的治疗和预防方法
EP4688856A1 (en) 2023-04-03 2026-02-11 Regeneron Pharmaceuticals, Inc. Methods of improving transplant survival using il-2 receptor gamma chain antibodies
CN117756915B (zh) * 2023-11-24 2025-05-30 河南省肿瘤医院 一组阻断抗pd-1抗体与细胞表面pd-1分子结合的pd-1分子及其突变体和用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
FR2796067B1 (fr) 1999-07-05 2001-09-07 Rhodia Chimie Sa Perfectionnement a l'echange et a la liberation d'une amine, de son fluorure de carbamoyle
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
PE20011338A1 (es) * 2000-05-26 2002-01-13 Bristol Myers Squibb Co Moleculas mutantes de ctla4 solubles
EP1793858A4 (en) 2004-09-08 2008-12-10 Univ Ohio State Res Found HUMAN MONOCLONAL ANTI-CTLA4 ANTIBODIES FOR CANCER TREATMENT
WO2006029220A2 (en) 2004-09-08 2006-03-16 Ohio State University Research Foundation Combination therapy with anti-ctla4 and anti-4-1bb antibodies
DK1915398T3 (en) * 2005-07-18 2016-07-04 Amgen Inc Humane anti-B7RP1 neutraliserende antistoffer
US8263073B2 (en) 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
CN101628940B (zh) 2008-07-15 2011-11-23 中国科学院生物物理研究所 一种单克隆抗体及其应用
EP2545073B1 (en) 2010-03-12 2015-09-30 AbbVie Biotherapeutics Inc. Ctla4 proteins and their uses
US9688740B2 (en) * 2011-10-26 2017-06-27 National Cancer Center Mutant CTLA4 gene transfected T cell and composition including same for anticancer immunotherapy
WO2013138702A2 (en) * 2012-03-15 2013-09-19 Bristol-Myers Squibb Company Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway
US10927154B2 (en) * 2014-01-13 2021-02-23 Pieris Pharmaceuticals Gmbh Multi-specific polypeptide useful for localized tumor immunomodulation
SI3389699T1 (sl) * 2015-12-15 2024-07-31 OncoC4, Inc. Himerna in humanizirana monoklonska protitelesa proti humanemu ctla4 in uporabe le - teh
EP3515489B1 (en) * 2016-09-19 2025-11-05 OncoC4, Inc. Cd80 and cd86 binding protein compositions and uses thereof
EP3746122A4 (en) * 2018-02-02 2021-11-24 OncoC4, Inc. SAFER AND MORE EFFECTIVE ANTI-CTLA-4 ANTIBODY SELECTION AND DESIGN PROCESSES FOR CANCER THERAPY

Also Published As

Publication number Publication date
EP3515489B1 (en) 2025-11-05
ES3059995T3 (en) 2026-03-24
US12441780B2 (en) 2025-10-14
EP3515489A4 (en) 2020-05-06
DK3515489T3 (da) 2026-01-26
CN109715210A (zh) 2019-05-03
US12227557B2 (en) 2025-02-18
US11261233B2 (en) 2022-03-01
CN109715210B (zh) 2023-05-30
EP3515489A1 (en) 2019-07-31
US20220259286A1 (en) 2022-08-18
WO2018053506A1 (en) 2018-03-22
CA3036997A1 (en) 2018-03-22
EP4667012A2 (en) 2025-12-24
US20220259285A1 (en) 2022-08-18
US20190263889A1 (en) 2019-08-29
EP4667012A3 (en) 2026-04-15
CN116942793A (zh) 2023-10-27

Similar Documents

Publication Publication Date Title
IL289276A (en) Treprostinil derivatives and compositions and uses thereof
IL262366A (en) Cd80 variant immunomodulatory proteins and uses thereof
IL262321A (en) Preparations and methods for selective protein expression
PL3443009T3 (pl) Przeciwciała i kompozycje anty-tim-3
IL248235B (en) Method and compositions for cellular immunotherapy
IL246921B (en) Binding proteins and methods of use thereof
PL3386534T3 (pl) Kompozycje i sposoby internalizacji enzymów
DK3186233T3 (da) Prober til billeddannelse af huntingtin-protein
IL253341B (en) Methods and compositions for combination immunotherapy
KR20180084891A (ko) 구조 조성물 및 방법
IL260124A (en) Compounds and methods for reducing tau expression
DK3274430T3 (da) Mikroalgesammensætninger og deres anvendelser
LT3240895T (lt) Kompozicijos ir būdai, skirti baltymų glikozilinimui
EP3503879A4 (en) COMPOSITION AND METHOD FOR IT
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
EP3256163A4 (en) Methods and compositions for modulating lilr proteins
IL250796A0 (en) Binding proteins specific for lox1 and uses thereof
DK3186241T3 (da) Prober til billeddannelse af huntington-protein
DK3515489T3 (da) Cd80- og cd86-bindende proteinsammensætinger og deres anvendelse
DK3197277T3 (da) Prober til billeddannelse af huntingtin-protein
IL258570A (en) Stable protein preparations
EP3522698A4 (en) NEW INSECTICIDE PROTEINS
IL257458B1 (en) Dpep-1 binding compositions and methods of use
EP3475418A4 (en) TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS AND THEIR USE
PL3638278T3 (pl) Kompozycje neuroprotekcyjne i ich zastosowanie